Layout Table~~~~2406~2406~~

Cannabinoids: A potential blockbuster?~
Published by Visiongain, February 2005

Today's cannabinoid market is undergoing rapid expansion. Currently just two products are available on this controversial market: Marinol from Unimed Pharmaceuticals and Nabilone marketed by Cambridge Laboratories. Both indicated for the control of chemotherapy- induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia associated with HIV/AIDS. However, the next coming months will witness the arrival of the world's first whole-cannabis plant derived pharmaceutical product, Sativex.

~

Published by Visiongain, February 2005

Today's cannabinoid market is undergoing rapid expansion. Currently just two products are available on this controversial market: Marinol from Unimed Pharmaceuticals and Nabilone marketed by Cambridge Laboratories. Both indicated for the control of chemotherapy- induced nausea and vomiting, Marinol has additional approval as an appetite stimulant to treat anorexia associated with HIV/AIDS. However, the next coming months will witness the arrival of the world's first whole-cannabis plant derived pharmaceutical product, Sativex.

The approval of Sativex upon the Canadian neuropathic pain associated Multiple Sclerosis market is imminent. Developed by the innovative cannabinoid company GW Pharmaceuticals, Sativex is expected to transform the market and aid recovery of loss of revenue following Pharmo's recent announcement of Dexananbinol's failure to show efficacy for Traumatic Brain Injury. The profile of the market will also be raised by the expected mid-2006 launch of Acomplia by Sanofi-Aventis for obesity. With such developments, cannabinoids are set to become pharmaceutical rather than political products and will encourage further R&D into this up-and coming area of industry. The DEA's decision to reschedule Marinol from Schedule II to Schedule III and the acceptance of medicinal cannabis in 11 US states demonstrates the shifting attitude required for the cannabinoids to achieve blockbuster status.

Visiongain values todays limited cannabinoid market at just $110.5m in 2005. Having grew 6.3% from 2004's revenues of $104 m, growth of the market will continue over the forecast period 2002-2010. Two forecast projections are made by visiongain in this report: if no comers arrive and the potential value following launch of the key future products.

Designed as an essential business aid, Cannabinoids: A Potential Blockbuster provides a thorough evaluation of the market. The report focuses on the following aspects:

* An Introduction to Cannabinoids
* Potential Cannabinoid Therapies
* The Worldwide Cannabinoid Market- Current and Future Products
* Pipeline Cannabinoid Products
* Cannabinoid Company Information
* Regulatory Issues of Cannabinoids and Medically Approved Cannabis in the Seven Major Markets

The report provides in-depth market analysis for current and potential products. The report extensively identifies cannabinoid drugs market potential by analysing the latest clinical trial research. The study also assess's the challenges faced by potential cannabinoid companies.

Why You Must Buy This Report?

This 150+ paged report features 29 tables, 17 graphs and charts, news, insights, the very latest developments and an indepth review of the cannabinoids market with upto date analysis. A survey of industry's leading representatives and their opinions of the cannabinoids gaining blockbuster status is provided. In addition, the latest updates and thoughts from the innovative cannabinoid company, GW Pharmaceuticals is detailed following visiongain's interview with a spokesperson from the company. This report is a vital addition to gaining an understanding of this up- and- coming sector of the pharmaceutical market, and will give your company 'the edge' of your competitiors. You can not afford to be without this latest report from visiongain.

Five key questions this report answer's are:
1. What is the market potential for cannabinoids treating various diseases?
2. What latest clinical trials/experimental research has been performed to develop cannabinoids for therapeutic uses?
3. What is the global cannabinoid market value of today and the future worth?
4. Will the cannabinoid market gain blockbuster status and why?
5. What are the regulatory issues surrounding cannabinoids and medicinal cannabis use in the seven major markets?

Sample Page 1
Sample Page 2
~Cannabinoids%3A A potential blockbuster? (Single user License PDF)|242|Cannabinoids%3A A potential blockbuster? (Department License PDF)|706| Cannabinoids%3A A potential blockbuster? (Company wide license PDF)|975|~2406~3044~~

Therapeutic Proteins~
~
Published by Visiongain, February 2005

Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.

In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues

Today therapeutic proteins are used to relieve patients suffering from many conditions, including:

Various cancers (Monoclonal antibodies, Interferons)

Heart attacks, strokes, cystic fibrosis, Gaucher's disease (Enzymes, Blood factors)
Diabetes (Insulin)
Anaemia (Erythropoietin)
Haemophilia (Blood clotting factors)
The leading therapeutic protein treatments in 2003 were:
Johnson & Johnson's anaemia treatment Procrit
Amgen's anaemia treatment Epogen
Schering-Plough's hepatitis treatments Intron A and Peg-Intron
The leading classes of therapeutic proteins in 2003 were:
Erythropoietins
Monoclonal antibodies
Interferons
While the top companies on the market were:
Amgen
Johnson & Johnson
Roche

WHY YOU MUST BUY THIS REPORT?

With over 80 graphs and figures, plus almost 60 tables, this report represents a key tool for companies wishing to enter into or expand in the therapeutic protein market. The reader will be left with a clear idea of:

The challenges faced by the therapeutic protein market, and how these are being overcome

The current and future market leaders in terms of brand, class, category and company, covering the period 2003-2010

Therapeutic targets currently being developed in the field and who is responsible for this developmen

The competition that companies will face during the forecast period from current and pipeline products

Sample Page
~Therapeutic Proteins%3A Single User license|208|Therapeutic Proteins%3A Comnpany Wide license|637|~2406~1882~~

Compound Management Trends~
Published by HTStec, December 2004

This market report summarizes the results of a global benchmarking web-based survey of Pharma and Biotech compound management groups. The objective of the study being to comprehensively document current practices, issues and future trends in compound management, with a particular focus on compound quality control and just-in-time compound delivery.~
Published by HTStec, December 2004

This market report summarizes the results of a global benchmarking web-based survey of Pharma and Biotech compound management groups. The objective of the study being to comprehensively document current practices, issues and future trends in compound management, with a particular focus on compound quality control and just-in-time compound delivery.

Highlights of this Report:

•The survey collected 70 responses (63 complete and 7 partially filled out) from 50 different Pharma and Biotech companies and 2 University/Research Institutes.
• Responses from were split geographically 44% North America and 56% Europe.
• Survey respondents were drawn from 32 Small-Medium Pharma/Biotechs, 31 Large Pharma, 2 Agrochemical Companies, 2 Contract Service Organisations, 2 University/Research Institutes and 1 Cosmetic Company.
• Respondents were either directly responsible for or directly involved in compound management within their company; or were closely involved in the preparation of assay ready plates from stocks provided by compound management. They represented 40 compound management groups; 20 screening groups; 3 corporate research management group; and 7 other groups.
• All data was presented and analyzed as the average response of All Survey Respondents. In addition, the data was fully reanalyzed after sub-division into the following 4 survey groups: 1) Large Pharma; 2) Small-Medium Pharma/Biotech; 3) Purchased Commercial Stores; and 4) Use of In House Alternatives.
• The mean size of a compound library today (2005) was 0.81 million compounds, this is expect to grow 1.42 million by 2008.
• Nearly one third of companies surveyed still use an ad hoc arrangement of lab freezers as the main component of their CM store.
• 60% of respondents had purchased a commercial CM store. REMP was the most popular commercial provider of the main component of their CM stores.
• Of the CM stores surveyed 68% represented a main (central) store, 27% a local site store and 5% a satellite lab store.
• Of the CM stores surveyed most used microplates and microtubes in part of the same facility;
• 89% of all liquid stocks today are in 100% DMSO (assumed starting concentration).
• The most common storage volume today is 0.1-0.5ml, this is also expected to be the case in 2008

 Table of Contents
~Compound Management Trends (Eletronic Site License PDF)|771|~2406~2614~~

The Directory Of Molecular Diversity Suppliers~
Published by Select Biosciences, June 2004

An extensive directory of companies supplying building blocks, screening compounds, synthetic libraries, natural products and ancillary services to the pharmaceutical and biotechnology markets.
~Published by Select Biosciences, June 2004

An extensive directory of companies supplying building blocks, screening compounds, synthetic libraries, natural products and ancillary services to the pharmaceutical and biotechnology markets.

• Over 90 companies analyzed
• Suppliers organized by :
    • Building Blocks
    • Natural Products
    • Peptides
    • Screening Compounds and Libraries
    • Library Design Services
    • Full Service Drug Discovery
• A unique and invaluable reference for purchasers of screening compounds
• An excellent source of competitive information for suppliers
• A useful comparative guide for investors
• Includes an Executive Analysis of trends in high throughput chemistry, screening and lead optimisation
• Personally compiled by Dr Wendy Warr, one of the leading consultants to the chemistry marketplace

Sample Pages

~The Directory Of Molecular Diversity Suppliers (Single User Print version)|816|The Directory Of Molecular Diversity Suppliers (Eletronic site license PDF)|817|~2406~2653~~